New drug duo targets Hard-to-Treat head and neck cancer
NCT ID NCT06194656
First seen Jan 19, 2026 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This phase II trial tests a new drug called SIBP-03, given together with cetuximab, for people with advanced head and neck cancer that has returned or spread. The study will enroll 81 adults who have already tried immunotherapy and platinum chemotherapy. The goal is to see if the combination can shrink tumors and control the disease longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, China
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SIBP-03 (HER3 monoclonal antibody) combined with cetuximab
What this could lead to
If it works, this could offer a new treatment option for people with advanced head and neck cancer that has stopped responding to standard therapies.
What could go wrong
This is an early Phase II study with only 81 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.